<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33821690</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5-6</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Intuitive Staging Correlates With King's Clinical Stage.</ArticleTitle><Pagination><StartPage>336</StartPage><EndPage>340</EndPage><MedlinePgn>336-340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1867181</ELocationID><Abstract><AbstractText><i>Background:</i> Clinical stage in amyotrophic lateral sclerosis (ALS) can be assigned using King's staging with a simple protocol based on the number of CNS regions involved and the presence of significant nutritional or respiratory failure. It is important that the assigned clinical stage matches expectations, and generally corresponds with how a health care professional would intuitively stage the patient. We therefore investigated the relationship between King's clinical ALS stage and ALS stage as intuitively assigned by health care professionals. <i>Methods:</i> We wrote 17 case vignettes describing people with ALS at different disease stages from very early limited disease involvement through to severe, multi-domain disease. During two workshops, we asked health care professionals to intuitively stage the vignettes and compared the answers with the actual King's clinical ALS stage. <i>Results:</i> There was a good correlation between King's clinical ALS stage and intuitively assigned stage, with a Spearman's Rank correlation coefficient of 0.64 (<i>p</i>&#x2009;&lt;&#x2009;0.001). There was no difference in the intuitive stages assigned by practitioners of different types or at different levels of experience. <i>Conclusions:</i> Across a spectrum of ALS scenarios, King's clinical ALS stage corresponds to intuitive ALS stage as assigned by a range of health care professionals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al Khleifat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balendra</LastName><ForeName>Rubika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Ton</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RP-PG-1016-20006</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107196/Z/14/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107196</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">King&#x2019;s stage</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">clinical stage</Keyword><Keyword MajorTopicYN="N">prognostic</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">ventilation</Keyword></KeywordList><CoiStatement>
<b>Disclosure of Interests</b>
. AAC is a consultant for Mitsubishi-Tanabe Pharma, GSK, and Chronos Therapeutics, and chief investigator for clinical trials for Cytokinetics and OrionPharma.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>6</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33821690</ArticleId><ArticleId IdType="mid">EMS123745</ArticleId><ArticleId IdType="pmc">PMC7611335</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1867181</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72. doi: 10.1056/NEJMra1603471. [Internet]</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, van den Berg LH, et al.  Amyotrophic lateral sclerosis: moving towards a new classification system.  [cited 2016 Sep 21];Lancet Neurol. 2016 Oct;15(11):1182&#x2013;94. [Internet], Available from:  http://linkinghub.elsevier.com/retrieve/pii/S1474442216301995.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Messina P, Logroscino G, Beghi E. Long-term survival in amyotrophic lateral sclerosis: A population-based study. Ann Neurol. 2014;75(2):287&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, et al.  A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016:1&#x2013;7. [Internet], Available from:  http://www.ncbi.nlm.nih.gov/pubmed/27378085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136716</ArticleId><ArticleId IdType="pubmed">27378085</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Al-Chalabi A, Hardiman O, Debray TP, van den Berg LH. The life expectancy of Stephen Hawking, according to the ENCALS model. The Lancet Neurology. 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">30033055</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(3):847&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Emilia Romagna Registry for ALSG et al.  Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. Eur J Neurol. 2016 [Internet], Available from:  http://www.ncbi.nlm.nih.gov/pubmed/27238551.</Citation><ArticleIdList><ArticleId IdType="pubmed">27238551</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H-P, Turner MR, Grosskreutz J, Abrahams S, Bede P, Govind V, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26746186</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Front Degener. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27415180</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis. [cited 2018 Sep 5];Biomark Med. 2018 Jul 1;12(7):693&#x2013;6. doi: 10.2217/bmm-2018-0149. [Internet]</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2018-0149</ArticleId><ArticleId IdType="pubmed">29856233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman, Balendra R, Jones A, Jivraj N, Steen IN, Young Ca, et al.  Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2014:jnnp-2013-306865.  [Internet]  http://jnnp.bmj.com/content/early/2014/01/24/jnnp-2013-306865%5Cn http://jnnp.bmj.com/content/early/2014/01/24/jnnp-2013-306865.full.pdf%5Cn http://www.ncbi.nlm.nih.gov/pubmed/24463480%5Cn http://jnnp.bmj.com/content/early/2014/01/24/jnnp-2013-306865.full?rs.</Citation><ArticleIdList><ArticleId IdType="pubmed">24463480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. The Lancet Neurology. 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Santangelo G, Caiazzo G, Siciliano M, Ferrantino T, Piccirillo G, et al. Neuropsychological assessment in different King&#x2019;s clinical stages of amyotrophic lateral sclerosis. [cited 2018 Sep 5];Amyotroph Lateral Scler Front Degener. 2016 May 18;17(3-4):228&#x2013;35. doi: 10.3109/21678421.2016.1143513. [Internet]</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1143513</ArticleId><ArticleId IdType="pubmed">26905940</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24641613</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wei QQ, Chen Y, Cao B, Ou RW, Hou Y, et al. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">30784318</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Calvo A, Moglia C, Manera U, Vasta R, Di Pede F, et al. Brain metabolic changes across King&#x2019;s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. Eur J Nucl Med Mol Imaging. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041703</ArticleId><ArticleId IdType="pubmed">33029654</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Higashihara M, van den Bos M, Geevasinga N, Kiernan MC, Vucic S. Cortical hyperexcitability evolves with disease progression in ALS. Ann Clin Transl Neurol. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261748</ArticleId><ArticleId IdType="pubmed">32304186</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, Murphy C, LiCALS U-M, Young C, et al. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph Lateral Scler Front Degener. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Antel J, Bradley W, Cardy P, Carpenter S, Chou S, et al. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124:96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS One. 2013;8(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al.  Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine: A Population-Based Study. JAMA Neurol. 2014;71(9):1&#x2013;9. [Internet], Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25048026.</Citation><ArticleIdList><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013:38&#x2013;44. [Internet], Available from:  http://www.ncbi.nlm.nih.gov/pubmed/24336810.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph Lateral Scler Front Degener. 2017;18(3-4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. Motor Neurone Disease: Assessment and Management (NG42) Natl Inst Heal Care Excell Guidel. 2016 Feb;:1&#x2013;48. [Internet] Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26962594.</Citation></Reference><Reference><Citation>Moore A, Young CA, Hughes DA. Health Utilities and Costs for Motor Neurone Disease. Value Heal. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31708062</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.  [cited 2018 Sep 13];Neurology. 2018 Sep 12; doi: 10.1212/WNL.0000000000006317. [Internet], Available from:  http://n.neurology.org/content/early/2018/09/12/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Consonni M, Dalla Bella E, Contarino VE, Bersano E, Lauria G. Cortical thinning trajectories across disease stages and cognitive impairment in amyotrophic lateral sclerosis. Cortex. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32811660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nfelder E, Osmanovic A, M&#xfc;schen LH, Petri S, Schreiber-Katz O. Costs of illness in amyotrophic lateral sclerosis (ALS): A cross-sectional survey in Germany. Orphanet J Rare Dis. 2020 Jun 12;15(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291655</ArticleId><ArticleId IdType="pubmed">32532288</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al.  Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3-4):279&#x2013;84. [Internet], Available from:  http://www.ncbi.nlm.nih.gov/pubmed/24720420.</Citation><ArticleIdList><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>